rts logo

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Analysis & Opinions from Experts

Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) is 32.76% higher on its value in year-to-date trading and has touched a low of $7.09 and a high of $14.45 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TEVA stock was last observed hovering at around $13.91 in the last trading session, with the day’s loss setting it -0.05%.

Currently trading at $13.86, the stock is 1.28% and 6.80% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.69 million and changing -0.36% at the moment leaves the stock 35.33% off its SMA200. TEVA registered 57.14% gain for a year compared to 6-month gain of 35.88%. The firm has a 50-day simple moving average (SMA 50) of $2.04 and a 200-day simple moving average (SMA200) of $20.79.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

The stock witnessed a 2.67% loss in the last 1 month and extending the period to 3 months gives it a 32.76%, and is -1.42% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.17% over the week and 2.39% over the month.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has around 37226 employees, a market worth around $15.54B and $15.84B in sales. Fwd P/E is 5.26. Profit margin for the company is -3.33%. Distance from 52-week low is 95.62% and -4.08% from its 52-week high. The company has generated returns on investments over the last 12 months (-2.03%).

Teva- Pharmaceutical Industries Ltd. ADR quarterly earnings per share for the current quarter are estimated at $0.52 with sales reaching $3.76B over the same period.The EPS is expected to shrink by -6.11% this year, but quarterly earnings will post -0.20% year-over-year. Quarterly sales are estimated to grow 3.70% in year-over-year returns.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Top Institutional Holders

625 institutions hold shares in Teva- Pharmaceutical Industries Ltd. ADR (TEVA), with institutional investors hold 53.42% of the company’s shares. The shares outstanding are 1.12B, and float is at 1.12B with Short Float at 0.93%. Institutions hold 53.42% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 40.29 million shares valued at $303.38 million. The investor’s holdings represent 3.59% of the TEVA Shares outstanding. As of Jun 29, 2023, the second largest holder is Phoenix Holdings Ltd. with 33.7 million shares valued at $253.79 million to account for 3.01% of the shares outstanding. The other top investors are Ion Asset Management Limited which holds 33.06 million shares representing 2.95% and valued at over $248.96 million, while Clal Insurance Enterprises Holdings Ltd holds 2.82% of the shares totaling 31.61 million with a market value of $238.06 million.

Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Insider Activity

The most recent transaction is an insider sale by Kalif Eliyahu Sharon,the company’sEVP, Chief Financial Officer. SEC filings show that Kalif Eliyahu Sharon sold 77,550 shares of the company’s common stock on Mar 06 ’24 at a price of $13.52 per share for a total of $1.05 million. Following the sale, the insider now owns 0.2 million shares.

Teva- Pharmaceutical Industries Ltd. ADR disclosed in a document filed with the SEC on Mar 05 ’24 that Sabag Mark (EVP, International Markets) sold a total of 100,000 shares of the company’s common stock. The trade occurred on Mar 05 ’24 and was made at $13.52 per share for $1.35 million. Following the transaction, the insider now directly holds 0.38 million shares of the TEVA stock.

Still, SEC filings show that on Mar 05 ’24, Daniell Richard (Exec. VP, European Commercial) disposed off 48,629 shares at an average price of $13.52 for $0.66 million. The insider now directly holds 69,770 shares of Teva- Pharmaceutical Industries Ltd. ADR (TEVA).

Related Posts